Ageing enhances the shedding of splenocyte microvesicles with endothelial pro-senescent effect that is prevented by a short-term intake of omega-3 PUFA EPA:DHA 6:1

Biochem Pharmacol. 2020 Mar:173:113734. doi: 10.1016/j.bcp.2019.113734. Epub 2019 Dec 5.

Abstract

Background: Ageing is associated with progressive endothelial senescence and dysfunction, and cardiovascular risk. Circulating endothelial microvesicles (MVs) are pro-senescent and pro-inflammatory endothelial effectors in acute coronary syndrome. Omega-3 PUFA intake was claimed beneficial in cardiovascular prevention.

Purpose: To investigate whether the intake of the omega-3 formulation EPA:DHA 6:1 by middle-aged and old rats reduces the shedding of pro-senescent microvesicles from cultured spleen leukocytes (SMVs) and clarify the underlying mechanisms in target coronary primary endothelial cells (ECs).

Methods: Middle-aged male Wistar rats (M, 48-week old) received 500 mg/kg/d of either EPA:DHA 6:1, EPA:DHA 1:1, or vehicle (CTL) for 7 days, old rats (72-week old) for 14 days. Spleen-derived leukocytes were prepared and cultured for 24 h and MVs collected from supernatants (SMVs). Cultured ECs were prepared from freshly isolated porcine coronary arteries. Senescence-associated β-galactosidase activity (SA-β-gal) was assessed by C12FDG, protein expression by Western blot analysis, oxidative stress by dihydroethidium using confocal microscopy, and procoagulant MVs by prothrombinase assay. The pro-senescent potential of SMVs from middle-aged rats (M-SMVs) was analyzed by comparison with young (Y, 12-week) and old (O) rats.

Results: The shedding of SMVs significantly increased with age and was inhibited by EPA:DHA 6:1 intake that also prevented ROS accumulation in spleen. Incubation of ECs with 10 nM SMVs from middle-aged and old but not those from young rats induced premature senescence after 48 h. The pro-senescent effect of M-SMVs was prevented by Losartan and associated with endothelial oxidative stress. M-SMVs induced an up-regulation of senescence markers (p16, p21, p53), pro-atherothrombotic (VCAM-1, ICAM-1, tissue factor) and pro-inflammatory markers (pNF-κB, COX-2) and proteins of the angiotensin system (ACE, AT1-R). Conversely, endothelial NO synthase was down-regulated. Intake of EPA:DHA 1:1 and 6:1 by middle-aged rats decreased SMV shedding by 14% and 24%, respectively. Only EPA:DHA 6:1 intake abolished the M-SMVs-induced endothelial senescence and reduced the pro-senescent action of O-SMVs by 45%. Protection of ECs was not observed in response to SMVs from EPA:DHA 1:1 treated rats.

Conclusion: Ingestion of EPA:DHA 6:1 by middle-aged or old rats, respectively abolished or limited both the shedding of SMVs and their pro-senescent, pro-thrombotic and pro-inflammatory effects in ECs, most likely by triggering the local angiotensin system. EPA:DHA 6:1 may help to delay ageing-related endothelial dysfunction.

Keywords: Angiotensin system; Endothelial senescence; Microparticles; Omega-3 polyunsaturated fatty acids; Oxidative stress; Spleen leukocyte.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / drug effects
  • Aging / physiology*
  • Animals
  • Antihypertensive Agents / pharmacology
  • Biomarkers / metabolism
  • Cell-Derived Microparticles / metabolism*
  • Cells, Cultured
  • Cellular Senescence / drug effects
  • Cellular Senescence / physiology*
  • Coronary Vessels / cytology
  • Coronary Vessels / metabolism
  • Docosahexaenoic Acids / administration & dosage
  • Docosahexaenoic Acids / chemistry
  • Eicosapentaenoic Acid / administration & dosage
  • Eicosapentaenoic Acid / chemistry
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Endothelial Cells / physiology
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-3 / chemistry
  • Losartan / pharmacology
  • Male
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Spleen / cytology
  • Spleen / drug effects
  • Spleen / metabolism*
  • Swine

Substances

  • Antihypertensive Agents
  • Biomarkers
  • Fatty Acids, Omega-3
  • Reactive Oxygen Species
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • Losartan